01 Growing Adoption of Multiplex Molecular Testing The infectious disease testing market is increasingly shifting toward multiplex molecular platforms capable of detecting multiple pathogens or targets from a single patient sample. These systems can shorten diagnostic workflows when symptoms overlap across different infections and can help clinicians distinguish between bacterial, viral, and other infectious causes. Broader multiplex capability is therefore increasing the clinical value of molecular testing in hospitals and diagnostic laboratories. In June 2024, the U.S. Food and Drug Administration authorized a multiplex molecular test capable of simultaneously detecting and differentiating respiratory viruses including influenza A, influenza B, respiratory syncytial virus, and SARS-CoV-2.
02 Increasing Use of Point-of-Care Infectious Disease Testing Infectious disease testing is increasingly moving closer to patients through point-of-care platforms that can deliver diagnostic results during a clinical visit. Faster testing can support earlier treatment decisions and reduce dependence on centralized laboratories for selected infections. This is particularly valuable in urgent-care, primary-care, emergency, and resource-limited settings where rapid clinical decisions are required. In September 2024, the U.S. Food and Drug Administration authorized a point-of-care molecular test for influenza A and B and respiratory syncytial virus that provides results in approximately 15 minutes.
01 Increasing Global Burden of Infectious Diseases The continued occurrence of infectious diseases creates sustained demand for diagnostic testing across hospitals, laboratories, public-health agencies, and community healthcare settings. Accurate testing supports disease identification, treatment selection, surveillance, and outbreak control. Persistent infectious disease activity therefore provides a fundamental source of demand for diagnostic technologies.
01 Limited Diagnostic Infrastructure in Low-Resource Settings Access to infectious disease testing remains constrained in regions with limited laboratory infrastructure, shortages of trained personnel, inconsistent electricity or connectivity, and restricted access to diagnostic equipment. These limitations can prevent timely testing even when suitable technologies exist. Infrastructure gaps therefore restrict the penetration of advanced infectious disease diagnostic platforms.
01 Expansion of At-Home Infectious Disease Testing The development of simple tests that can be performed outside traditional healthcare facilities creates opportunities to expand infectious disease screening and diagnosis. At-home testing can improve convenience, increase access for individuals who may not immediately visit a healthcare provider, and support earlier identification of selected infections. Regulatory acceptance of reliable self-testing technologies can further expand this opportunity.
01 Antimicrobial Resistance Increases the Need for Accurate Pathogen Identification The spread of antimicrobial resistance makes it increasingly important to determine the causative pathogen and, where appropriate, its susceptibility to available treatments. Diagnostic uncertainty can contribute to inappropriate antimicrobial use and delay effective therapy. Testing developers therefore face the challenge of providing sufficiently rapid and accurate information to support antimicrobial stewardship without adding excessive complexity to clinical workflows.
June 2026 Abbott expanded its infectious disease diagnostics portfolio by launching advanced testing solutions featuring improved accuracy, faster turnaround times, and enhanced molecular diagnostic capabilities. The company focused on supporting hospitals, laboratories, and healthcare providers with efficient detection tools for infectious diseases.
April 2026 Roche expanded its molecular diagnostics portfolio by introducing next-generation infectious disease testing technologies featuring improved automation, multiplex testing capabilities, and enhanced laboratory workflow efficiency. The company focused on enabling faster and more precise disease identification.
January 2026 Thermo Fisher Scientific expanded its clinical diagnostics portfolio by developing advanced infectious disease testing solutions using molecular technologies and automation platforms. The company focused on improving diagnostic accuracy and supporting global disease surveillance efforts.
October 2025 Danaher expanded its diagnostics portfolio through its healthcare businesses by advancing infectious disease testing platforms featuring improved molecular detection, automation, and data integration capabilities for clinical laboratories.